These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8260445)

  • 21. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
    Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
    J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment.
    Perényi A; Frecska E; Bagdy G; Révai K
    Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of neurological signs with clozapine treatment.
    Buchanan RW; Koeppl P; Breier A
    Biol Psychiatry; 1994 Aug; 36(3):198-200. PubMed ID: 7948457
    [No Abstract]   [Full Text] [Related]  

  • 27. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.
    Ahmed S; Chengappa KN; Naidu VR; Baker RW; Parepally H; Schooler NR
    J Clin Psychiatry; 1998 Sep; 59(9):472-7. PubMed ID: 9771818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment of tardive dyskinesia.
    Raja M
    Schweiz Arch Neurol Psychiatr (1985); 1996; 147(1):13-8. PubMed ID: 8685689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
    Cassady SL; Thaker GK; Tamminga CA
    Psychopharmacol Bull; 1993; 29(2):235-40. PubMed ID: 8290671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of neuroleptic therapy in the self assessment of schizophrenic patients].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1987 Aug; 39(8):487-91. PubMed ID: 3685210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of relapse in schizophrenia.
    Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of clozapine-associated tardive dyskinesia.
    Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744
    [No Abstract]   [Full Text] [Related]  

  • 36. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine in tardive Tourette syndrome.
    Jaffe E; Trémeau F; Sharif Z; Reider R
    Biol Psychiatry; 1995 Aug; 38(3):196-7. PubMed ID: 7578666
    [No Abstract]   [Full Text] [Related]  

  • 39. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
    Newcomer JW; Miller LS; Faustman WO; Wetzel MW; Vogler GP; Csernansky JG
    Br J Psychiatry; 1994 Jun; 164(6):834-8. PubMed ID: 7952993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.